

Patient	Age/ Gender	Stage	Regimen	Baseline CREBBP	Baseline TP53	Final CREBBP	Final TP53	TMB count	tFL	PFS (months)
11	39/F	4	BR	■	■	■	■	14	■	3
13	45/F	3	BR	■	■	■	■	10	■	3
14	34/F	4	BR	■	■	■	■	20	■	6
6	62/F	4	BR	■	■	■	■	12	■	6
12	39/F	4	BR	■	■	■	■	12	■	10
3	65/M	4	BR	■	■	■	■	4	■	15
2	70/F	4	RCHOP	■	■	■	■	25	■	7
7	41/F	4	RCVP	■	■	■	■	1	■	14
9	35/M	4	RCHOP	■	■	■	■	4	■	15
8	53/M	4	RCHOP	■	■	■	■	8	■	16
4	70/M	2	RCHOP	■	■	■	■	3	■	24
1	66/M	4	RCHOP	■	■	■	■	3	■	27
5	64/M	4	RCHOP	■	■	■	■	7	■	29
10	46/F	3	RCVP	■	■	■	■	3	■	109

BR, bendamustine, rituximab; RCHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; RCVP, rituximab, cyclophosphamide, vincristine, prednisolone; TMB, tumor mutation burden; tFL, transformed follicular lymphoma; PFS, progression-free survival

S1 Fig. Summary of 14 patients with relapse or disease progression. BR, bendamustine and rituximab; PFS, progression-free survival; RCHOP, rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone; RCVP, cyclophosphamide, vincristine, and prednisolone; tFL, transformed follicular lymphoma; TMB, tumor mutation burden.